Literature DB >> 21919870

The role of p-glycoprotein in psychiatric disorders: a reliable guard of the brain?

Onno L De Klerk1, Fokko J Bosker, Gert Luurtsema, Ilja M Nolte, Rudi Dierckx, Johan A Den Boer, Heidrun Potschka.   

Abstract

A major component in the protection of the brain against blood-borne toxic influences is the multispecific efflux pump P-glycoprotein. This pump, a 170 kD protein, located at the luminal side of the capillary endothelial cells, has a large capacity and is capable of extruding a wide array of structurally divergent substrates. The brain uptake of the majority of antidepressants and antipsychotics, as well as many other psychotropic drugs and endogenous compounds is hampered by the activity of P-glycoprotein. In this review we discuss the current state of knowledge concerning the role of Pglycoprotein on pharmacokinetics of psychiatric drugs and the impact of modulation of P-glycoprotein on major psychiatric disorders. Relevant issues in reference to the function of P-glycoprotein and other efflux pumps in the blood-brain barrier related to mood disorders and schizophrenia are addressed, such as a possible role of P-glycoprotein as a susceptibility factor in depressive disorders and psychotic disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21919870     DOI: 10.2174/187152411798047744

Source DB:  PubMed          Journal:  Cent Nerv Syst Agents Med Chem        ISSN: 1871-5249


  6 in total

1.  The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.

Authors:  Natalia I Brzozowska; Erik J de Tonnerre; Kong M Li; Xiao Suo Wang; Aurelie A Boucher; Paul D Callaghan; Michael Kuligowski; Alex Wong; Jonathon C Arnold
Journal:  Neuropsychopharmacology       Date:  2017-03-08       Impact factor: 7.853

2.  P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia.

Authors:  Gwen McCaffrey; William D Staatz; Lucy Sanchez-Covarrubias; Jessica D Finch; Kristen Demarco; Mei-Li Laracuente; Patrick T Ronaldson; Thomas P Davis
Journal:  J Neurochem       Date:  2012-07-10       Impact factor: 5.372

Review 3.  Sex Differences in Blood-Brain Barrier Transport of Psychotropic Drugs.

Authors:  Christina Dalla; Pavlina Pavlidi; Danai-Georgia Sakelliadou; Tatiana Grammatikopoulou; Nikolaos Kokras
Journal:  Front Behav Neurosci       Date:  2022-05-23       Impact factor: 3.617

Review 4.  Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery.

Authors:  Gwen McCaffrey; Thomas P Davis
Journal:  J Investig Med       Date:  2012-12       Impact factor: 2.895

5.  Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study.

Authors:  Beate Beer; Robert Erb; Marion Pavlic; Hanno Ulmer; Salvatore Giacomuzzi; Yvonne Riemer; Herbert Oberacher
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

6.  Restraint Stress-Induced Morphological Changes at the Blood-Brain Barrier in Adult Rats.

Authors:  Petra Sántha; Szilvia Veszelka; Zsófia Hoyk; Mária Mészáros; Fruzsina R Walter; Andrea E Tóth; Lóránd Kiss; András Kincses; Zita Oláh; György Seprényi; Gábor Rákhely; András Dér; Magdolna Pákáski; János Kálmán; Ágnes Kittel; Mária A Deli
Journal:  Front Mol Neurosci       Date:  2016-01-14       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.